{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:15:23Z","timestamp":1776082523678,"version":"3.50.1"},"reference-count":157,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The use of antifungal drugs started in the 1950s with polyenes nystatin, natamycin and amphotericin B-deoxycholate (AmB). Until the present day, AmB has been considered to be a hallmark in the treatment of invasive systemic fungal infections. Nevertheless, the success and the use of AmB were associated with severe adverse effects which stimulated the development of new antifungal drugs such as azoles, pyrimidine antimetabolite, mitotic inhibitors, allylamines and echinochandins. However, all of these drugs presented one or more limitations associated with adverse reactions, administration route and more recently the development of resistance. To worsen this scenario, there has been an increase in fungal infections, especially in invasive systemic fungal infections that are particularly difficult to diagnose and treat. In 2022, the World Health Organization (WHO) published the first fungal priority pathogens list, alerting people to the increased incidence of invasive systemic fungal infections and to the associated risk of mortality\/morbidity. The report also emphasized the need to rationally use existing drugs and develop new drugs. In this review, we performed an overview of the history of antifungals and their classification, mechanism of action, pharmacokinetic\/pharmacodynamic (PK\/PD) characteristics and clinical applications. In parallel, we also addressed the contribution of fungi biology and genetics to the development of resistance to antifungal drugs. Considering that drug effectiveness also depends on the mammalian host, we provide an overview on the roles of therapeutic drug monitoring and pharmacogenomics as means to improve the outcome, prevent\/reduce antifungal toxicity and prevent the emergence of antifungal resistance. Finally, we present the new antifungals and their main characteristics.<\/jats:p>","DOI":"10.3390\/antibiotics12050884","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T03:32:27Z","timestamp":1683689547000},"page":"884","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Antifungals: From Pharmacokinetics to Clinical Practice"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7704-4736","authenticated-orcid":false,"given":"An\u00e1lia","family":"Carmo","sequence":"first","affiliation":[{"name":"Advanced Unit for Pharmacokinetics and Personalized Therapeutics, Clinical Pathology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, 3004-561 Coimbra, Portugal"}]},{"given":"Marilia","family":"Rocha","sequence":"additional","affiliation":[{"name":"Advanced Unit for Pharmacokinetics and Personalized Therapeutics, Pharmacy Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, 3004-561 Coimbra, Portugal"}]},{"given":"Patricia","family":"Pereirinha","sequence":"additional","affiliation":[{"name":"Advanced Unit for Pharmacokinetics and Personalized Therapeutics, Pharmacy Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, 3004-561 Coimbra, Portugal"}]},{"given":"Rui","family":"Tom\u00e9","sequence":"additional","affiliation":[{"name":"Clinical Pathology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, 3004-561 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-8583","authenticated-orcid":false,"given":"Eul\u00e1lia","family":"Costa","sequence":"additional","affiliation":[{"name":"Advanced Unit for Pharmacokinetics and Personalized Therapeutics, Clinical Pathology Department, Centro Hospitalar e Universit\u00e1rio de Coimbra, 3004-561 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41564-021-00888-x","article-title":"Fungal taxonomy and sequence-based nomenclature","volume":"6","author":"Aime","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0007-1528(72)80012-9","article-title":"A scheme for the numerical classification of fungi","volume":"6","author":"Jefferys","year":"1972","journal-title":"Bull. Br. Mycol. Soc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/j.2050-0416.1971.tb06946.x","article-title":"Yeast classification","volume":"77","author":"Gilliland","year":"1971","journal-title":"J. Inst. Brew."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1128\/br.5.2.97-179.1941","article-title":"The Yeasts Genetics, Cytology, Variation, Classification and Identification","volume":"5","author":"Henrici","year":"1941","journal-title":"Bacteriol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Talbot, P.H.B. (1971). Principles of Fungal Taxonomy, Palgrave.","DOI":"10.1007\/978-1-349-15432-6"},{"key":"ref_6","unstructured":"Ainsworth, G.C., Hawksworth, D.L., Kirk, P.M., Sutton, B.C., and Pegler, D.N. (1971). Ainsworth & Bisby\u2019s Dictionary of the Fungi, Commonwealth Agricultural Bureaux [for the] Commonwealth Mycological Institute. [6th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"fov050","DOI":"10.1093\/femsyr\/fov050","article-title":"Advances in yeast systematics and phylogeny and their use as predictors of biotechnologically important metabolic pathways","volume":"15","author":"Kurtzman","year":"2015","journal-title":"FEMS Yeast Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1023\/A:1018310018202","article-title":"Fungi and international biodiversity initiatives","volume":"6","author":"Hawksworth","year":"1997","journal-title":"Biodivers. Conserv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28513415","DOI":"10.1128\/microbiolspec.FUNK-0035-2016","article-title":"The Fungal Cell Wall: Structure, Biosynthesis, and Function","volume":"5","author":"Gow","year":"2017","journal-title":"Microbiol. Spectr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3389\/fmicb.2019.02993","article-title":"The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species","volume":"10","author":"Rivera","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/jam.13301","article-title":"Fungal cell membrane-promising drug target for antifungal therapy","volume":"121","author":"Sant","year":"2016","journal-title":"J. Appl. Microbiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients","volume":"909","author":"Marr","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1097\/01.TP.0000065178.93741.72","article-title":"Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: Prospective, multicenter, case-controlled study","volume":"75","author":"Husain","year":"2003","journal-title":"Transplantation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","article-title":"Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study","volume":"39","author":"Kett","year":"2011","journal-title":"Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: An epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: Results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: A Potential Risk Factor for Hospital Mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2019.06.009","article-title":"National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: Evidence of sub-optimal practice","volume":"79","author":"Schelenz","year":"2019","journal-title":"J. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Fioriti, S., Brescini, L., Pallotta, F., Canovari, B., Morroni, G., and Barchiesi, F. (2022). Antifungal Combinations against Candida Species: From Bench to Bedside. J. Fungi, 8.","DOI":"10.3390\/jof8101077"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1517\/17425250903463878","article-title":"Pharmacology and clinical use of voriconazole","volume":"6","author":"Thompson","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Poissy, J., Rouz\u00e9, A., Cornu, M., Nseir, S., and Sendid, B. (2022). The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance. J. Fungi, 8.","DOI":"10.3390\/jof8090946"},{"key":"ref_23","first-page":"28","article-title":"Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines","volume":"4","author":"Vasileiou","year":"2018","journal-title":"Curr. Med. Mycol."},{"key":"ref_24","unstructured":"CDC (2019). Antibiotic Resistance Threats in the United States, 2019, U.S. Department of Health and Human Services, CDC."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e0005322","DOI":"10.1128\/aac.00053-22","article-title":"Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents","volume":"66","author":"Jacobs","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e01393-19","DOI":"10.1128\/AAC.01393-19","article-title":"In Vitro Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against Candida auris Shows No Antagonism","volume":"63","author":"Bidaud","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","article-title":"Hidden Killers: Human Fungal Infections","volume":"4","author":"Brown","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jinf.2012.08.003","article-title":"Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry","volume":"65","author":"Steinbach","year":"2012","journal-title":"J. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2110-5820-2-6","article-title":"Invasive fungal disease in PICU: Epidemiology and risk factors","volume":"2","author":"Brissaud","year":"2012","journal-title":"Ann. Intensiv. Care"},{"key":"ref_30","first-page":"30300","article-title":"Emerging Aspergillosis by Azole-Resistant Aspergillus Fumigatus at an Intensive Care Unit in the Netherlands, 2010 to 2013","volume":"21","author":"Russcher","year":"2016","journal-title":"Eurosurveillance"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the development of azole derivatives","volume":"10","author":"Maertens","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3904\/kjim.2017.109","article-title":"Voriconazole-refractory invasive aspergillosis","volume":"32","author":"Park","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/s41598-020-73098-w","article-title":"Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis","volume":"10","author":"Shin","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bongomin, F., Gago, S., Oladele, R.O., and Denning, D.W. (2017). Global and Multi-National Prevalence of Fungal Diseases\u2014Estimate Precision. J. Fungi, 3.","DOI":"10.3390\/jof3040057"},{"key":"ref_36","first-page":"529","article-title":"Echinocandins","volume":"28","author":"Russi","year":"2011","journal-title":"Rev. Chil. Infect."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/CMR.1.2.187","article-title":"Overview of Medically Important Antifungal Azole Derivatives","volume":"1","author":"Fromtling","year":"1988","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/0190-9622(90)70286-Q","article-title":"History of antifungals","volume":"23","author":"Smith","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/02652049809006844","article-title":"Development of Liposomal Amphotericin B Formulation","volume":"15","author":"Bajadt","year":"1998","journal-title":"J. Microencapsul."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijantimicag.2008.01.023","article-title":"Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis","volume":"31","author":"Giusiano","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014Structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Chmielewska","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Aris, P., Wei, Y., Mohamadzadeh, M., and Xia, X. (2022). Griseofulvin: An Updated Overview of Old and Current Knowledge. Molecules, 27.","DOI":"10.3390\/molecules27207034"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: A Review of Its Pharmacology, Clinical Indications, Pharmacokinetics, Toxicity and Drug Interactions","volume":"46","author":"Vermesa","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1378\/chest.54.Supplement_1.296","article-title":"The Discovery and Development of Amphotericin B","volume":"54","author":"Dutcher","year":"1968","journal-title":"Dis. Chest"},{"key":"ref_45","first-page":"173","article-title":"Amphotericin B, the Wonder of Today\u2019s Pharmacology Science: Persisting Usage for More Than Seven Decades","volume":"6","year":"2020","journal-title":"Pharm. Biomed. Res."},{"key":"ref_46","first-page":"404","article-title":"Antifungal Agents","volume":"187","author":"Chen","year":"2007","journal-title":"MJA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"a019653","DOI":"10.1101\/cshperspect.a019653","article-title":"Antifungal Pharmacokinetics and Pharmacodynamics","volume":"5","author":"Lepak","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4064628","DOI":"10.1155\/2017\/4064628","article-title":"Increasing the Fungicidal Action of Amphotericin B by Inhibiting the Nitric Oxide-Dependent Tolerance Pathway","volume":"2017","author":"Vriens","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2161671","DOI":"10.1080\/10717544.2022.2161671","article-title":"Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application","volume":"30","author":"Zhong","year":"2023","journal-title":"Drug Deliv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/jeccm.2019.08.01","article-title":"Antifungal drug dosing adjustment in critical patients with invasive fungal infections","volume":"3","author":"Pyrpasopoulou","year":"2019","journal-title":"J. Emerg. Crit. Care Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40272-020-00379-2","article-title":"Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients","volume":"22","author":"Downes","year":"2020","journal-title":"Pediatr. Drugs"},{"key":"ref_53","first-page":"519","article-title":"Intrathecal Amphotericin B: A 60-Year Experience in Treating Coccidioidal Meningitis","volume":"64","author":"Ho","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1097\/INF.0000000000003659","article-title":"New Developments in Pediatric Antifungal Pharmacology","volume":"41","author":"Groll","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1054-3589(08)60129-5","article-title":"Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development","volume":"44","author":"Groll","year":"1998","journal-title":"Adv. Pharm."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/jac\/dkt221","article-title":"Flucytosine and cryptococcosis: Time to urgently address the worldwide accessibility of a 50-year-old antifungal","volume":"68","author":"Loyse","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Miot, J., Leong, T., Takuva, S., Parrish, A., and Dawood, H. (2021). Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-06268-9"},{"key":"ref_58","unstructured":"Gentles, J.C. (1980). Human and Animal Mycology: In Proceedings of the VII Congress of ISHAM, Jerusalem, Israel, 11\u201316 March 1979, Excerpta Medica."},{"key":"ref_59","first-page":"851","article-title":"Griseofulvin: A New look at an Old Drug","volume":"24","author":"Araujo","year":"1990","journal-title":"DlCP Ann. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/clinids\/9.Supplement_1.S4","article-title":"Evolution of Antifungal Agents: Past, Present, and Future","volume":"9","author":"Drouhet","year":"1987","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-9258(18)72045-0","article-title":"Some biological effects produced by benzimidazole and their reversal by purines","volume":"152","author":"Woolley","year":"1944","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/iai.4.2.143-148.1971","article-title":"In Vitro Antifungal Activity of Clotrimazole (Bay b 5097)","volume":"4","author":"Shadomy","year":"1971","journal-title":"Infect. Immun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/14787210.4.2.171","article-title":"Miconazole: A historical perspective","volume":"4","author":"Fothergill","year":"2006","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003495-197816030-00001","article-title":"Econazole: A Review of Its Antifungal Activity and Therapeutic Efficacy","volume":"16","author":"Heel","year":"1978","journal-title":"Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1172\/JCI110903","article-title":"Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes","volume":"71","author":"Loose","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/313748","article-title":"Introduction to Antifungal Drugs","volume":"30","author":"Dismukes","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0016-5085(84)80021-9","article-title":"Hepatic Injury Associated With Ketoconazole Therapy","volume":"86","author":"Lewis","year":"1984","journal-title":"Gastroenterology"},{"key":"ref_68","unstructured":"(2023, April 30). European Medicines Agency\u2019s Committee on Medicinal Products for Human Use Suspension of Marketing Authorisations for Oral Ketoconazole Benefit of Oral Ketoconazole Does Not Outweigh Risk of Liver Injury in Fungal Infections On 25 July 2013, the European Medicines Agency\u2019s Committee on Medicinal Products for Human Use; 2013. Available online: https:\/\/www.ema.europa.eu\/en\/news\/european-medicines-agency-recommends-suspension-marketing-authorisations-oral-ketoconazole."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/infdis\/157.1.178","article-title":"Fluconazole Penetration into Cerebrospinal Fluid: Implications for Treating Fungal Infections of the Central Nervous System","volume":"157","author":"Arndt","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/17425255.2018.1492551","article-title":"Pharmacokinetics\u2013pharmacodynamics of antifungal agents in the central nervous system","volume":"14","author":"Hope","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1128\/AAC.28.5.648","article-title":"Pharma-cokinetic Evaluation of UK-49,858, a Metabolically Stable Triazole Antifungal Drug, in Animals and Humans","volume":"28","author":"Humphrey","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.32.1.1","article-title":"Azole Antifungal Agents: Emphasis on New Triazoles","volume":"32","author":"Saag","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/514744","article-title":"Itraconazole Prophylaxis for Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection: Randomized, Placebo-Controlled, Double-Blind Study","volume":"28","author":"McKinsey","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/08998280.2003.11927910","article-title":"Voriconazole: The Newest Triazole Antifungal Agent","volume":"16","author":"Greer","year":"2003","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current Concepts in Antifungal Pharmacology","volume":"86","author":"Russell","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles","volume":"57","author":"Camps","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study","volume":"68","author":"Lestrade","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e00917-19","DOI":"10.1128\/AAC.00917-19","article-title":"Efficacy of Voriconazole against Aspergillus Fumigatus Infection Depends on Host Immune Function","volume":"64","author":"Rosowski","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/ajt.14940","article-title":"Failure of voriconazole therapy due to acquired azole resistance in Aspergillus fumigatus in a kidney transplant recipient with chronic necrotizing aspergillosis","volume":"18","author":"Pilmis","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus Voriconazole for Primary Treatment of Invasive Aspergillosis: A Phase 3, Randomised, Controlled, Non-Inferiority Trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3314\/mmj.21-00004","article-title":"Efficacy of Posaconazole against Rhizopus oryzae Infection in Silkworm","volume":"62","author":"Kurakado","year":"2021","journal-title":"Med. Mycol. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4236\/pp.2020.115007","article-title":"Pharmacokinetic\/Pharmacodynamic Analysis the Probability of Target Attainment of Posaconazole against Mucorales Species in Patients with Mucormycosis","volume":"11","author":"Wang","year":"2020","journal-title":"Pharmacol. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00128071-200304010-00005","article-title":"Terbinafine: A Review of Its Use in Onychomycosis in Adults","volume":"4","author":"Darkes","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_85","first-page":"CD004685","article-title":"Systemic antifungal therapy for tinea capitis in children","volume":"2016","author":"Chen","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fphar.2019.00080","article-title":"The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?","volume":"10","author":"Guerriero","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS\u00ae)\u2014A case study","volume":"31","author":"Balkovec","year":"2013","journal-title":"Nat. Prod. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ja.2008.3","article-title":"Micafungin: A sulfated echinocandin","volume":"62","author":"Hashimoto","year":"2009","journal-title":"J. Antibiot."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1086\/505204","article-title":"Reviews Of Anti-infective Agents: Anidulafungin: A Novel Echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","article-title":"Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial","volume":"73","author":"Thompson","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11908-016-0549-2","article-title":"Echinocandin Resistance in Candida Species: A Review of Recent Developments","volume":"18","author":"Wiederhold","year":"2016","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e02644-16","DOI":"10.1128\/AAC.02644-16","article-title":"Molecular Confirmation of the Relationship between Candida guilliermondii Fks1p Naturally Occurring Amino Acid Substitutions and Its Intrinsic Reduced Echinocandin Susceptibility","volume":"61","author":"Dudiuk","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","article-title":"Treatment strategies for cryptococcal infection: Challenges, advances and future outlook","volume":"19","author":"Iyer","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/17425255.2021.1890715","article-title":"Current approaches and future strategies for the implementation of pharmacogenomics in the clinical use of azole antifungal drugs","volume":"17","author":"Borobia","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later","volume":"107","author":"Relling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12281-020-00371-w","article-title":"Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?","volume":"14","author":"Miller","year":"2020","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40121-020-00280-y","article-title":"Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?","volume":"9","author":"Vena","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cca.2019.01.023","article-title":"Advances in antifungal drug measurement by liquid chromatography-mass spectrometry","volume":"491","author":"Zheng","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Yasu, T., Nomura, Y., Gando, Y., Matsumoto, Y., Sugita, T., Kosugi, N., and Kobayashi, M. (2022). High-Performance Liquid Chromatography for Ultra-Simple Determination of Plasma Voriconazole Concentration. J. Fungi, 8.","DOI":"10.3390\/jof8101035"},{"key":"ref_101","unstructured":"Clarke, W., Molinaro, R., Bachmann, L., Botelho, J., Cao, Z., French, D., Garg, S., Gawoski, J., and Grant, R. (2014). C62-A Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline, Clinical and Laboratory Standards Institute."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.clinbiochem.2008.09.004","article-title":"The role of proficiency testing in achieving standardization and harmonization between laboratories","volume":"42","author":"Miller","year":"2009","journal-title":"Clin. Biochem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clinms.2019.04.003","article-title":"A proposal to standardize the description of LC\u2013MS-based measurement methods in laboratory medicine","volume":"13","author":"Vogeser","year":"2019","journal-title":"Clin. Mass Spectrom."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/CMR.00059-05","article-title":"Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy","volume":"19","author":"Meletiadis","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_105","unstructured":"McKeny, P.T., Nessel, T.A., and Zito, P.M. (2022). Antifungal Antibiotics, StatPearls Publishing. [Updated 31 October 2022]."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokinetic\/Pharmacodynamic Profile of Posaconazole","volume":"49","author":"Li","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: Focus on drugs without a clear recommendation","volume":"26","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin. Ther."},{"key":"ref_111","first-page":"7823","article-title":"Toxic Optic Neuropathy Due to Voriconazole: Possible Potentiation by Reduction of CYP2C19 Activity","volume":"25","author":"Orssaud","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FTD.0000000000000931","article-title":"Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","volume":"44","author":"Kim","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamadermatol.2018.3578","article-title":"Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections","volume":"154","author":"Stolmeier","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1021\/acs.chemrev.0c00199","article-title":"Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond","volume":"121","author":"Lee","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/dky517","article-title":"Emerging threat of triazole-resistant Aspergillus fumigatus","volume":"74","author":"Rybak","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/encyclopedia2040118","article-title":"Antifungals and Drug Resistance","volume":"2","author":"Hossain","year":"2022","journal-title":"Encyclopedia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1164\/rccm.201510-2104LE","article-title":"Voriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection","volume":"193","author":"Kolwijck","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s12223-020-00785-6","article-title":"Assessment of antifungal resistance and associated molecular mechanism in Candida albicans isolates from different cohorts of patients in North Indian state of Haryana","volume":"65","author":"Kumar","year":"2020","journal-title":"Folia Microbiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1128\/AAC.39.12.2708","article-title":"Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility","volume":"39","author":"Geber","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"R1520","DOI":"10.1016\/j.cub.2021.09.071","article-title":"Antifungal drug resistance: Deciphering the mechanisms governing multidrug resistance in the fungal pathogen Candida glabrata","volume":"31","author":"Robbins","year":"2021","journal-title":"Curr. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/mmy\/myx119","article-title":"Aspergillus terreus: Novel lessons learned on amphotericin B resistance","volume":"56","author":"Posch","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"103243","DOI":"10.1016\/j.fgb.2019.103243","article-title":"Candida auris and multidrug resistance: Defining the new normal","volume":"131","author":"Lockhart","year":"2019","journal-title":"Fungal Genet. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3389\/fmicb.2019.02788","article-title":"Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris","volume":"10","author":"Chaabane","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/13543784.2020.1791819","article-title":"Innovative therapies for invasive fungal infections in preclinical and clinical development","volume":"29","author":"Yu","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Delma, F.Z., Al-Hatmi, A.M.S., Br\u00fcggemann, R.J.M., Melchers, W.J.G., de Hoog, S., Verweij, P.E., and Buil, J.B. (2021). Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi. J. Fungi, 7.","DOI":"10.3390\/jof7110909"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41467-019-13890-z","article-title":"5-fluorocytosine resistance is associated with hypermutation and alterations in capsule biosynthesis in Cryptococcus","volume":"11","author":"Billmyre","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_129","unstructured":"National Institutes of Health, Centers for Disease Control and Prevention, and HIV Medicine Association of the Infectious Diseases Society of America Panel (2023, April 30). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available online: https:\/\/www.idsociety.org\/practice-guideline\/prevention-and-treatment-of-opportunistic-infections-among-adults-and-adolescents\/."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ruma, Y.N., Keniya, M.V., Tyndall, J.D.A., and Monk, B.C. (2022). Characterisation of Candida parapsilosis CYP51 as a Drug Target Using Saccharomyces cerevisiae as Host. J. Fungi, 8.","DOI":"10.3390\/jof8010069"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fmicb.2019.00691","article-title":"The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Paul, S., Shaw, D., Joshi, H., Singh, S., Chakrabarti, A., Rudramurthy, S.M., and Ghosh, A.K. (2022). Mechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0269721"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dkx480","article-title":"A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009\u201317) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance","volume":"73","author":"Chowdhary","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_134","first-page":"105807","article-title":"Azole resistance mechanisms in Aspergillus: Update and recent advances","volume":"55","author":"Capilla","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkt075","article-title":"The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus","volume":"68","author":"Fraczek","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wiederhold, N.P. (2020). Review of the Novel Investigational Antifungal Olorofim. J. Fungi, 6.","DOI":"10.3390\/jof6030122"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"ofy187","DOI":"10.1093\/ofid\/ofy187","article-title":"Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network","volume":"5","author":"Webb","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.2147\/IDR.S381851","article-title":"Efficacy and Safety of Combination Antifungals as Empirical, Preemptive, and Targeted Therapies for Invasive Fungal Infections in Intensive-Care Units","volume":"15","author":"Yang","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jiac.2020.01.015","article-title":"Echinocandins versus non-echinocandins for empirical antifungal therapy in patients with hematological disease with febrile neutropenia: A systematic review and meta-analysis","volume":"26","author":"Yamashita","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12281-020-00379-2","article-title":"Azole-Resistant Aspergillus and Echinocandin-Resistant Candida: What Are the Treatment Options?","volume":"14","author":"Novak","year":"2020","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Ben-Ami, R. (2023). Systemic Antifungal Therapy for Invasive Pulmonary Infections. J. Fungi, 9.","DOI":"10.3390\/jof9020144"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"451","DOI":"10.14740\/jocmr2992w","article-title":"Combination Antifungal Therapy: A Review of Current Data","volume":"9","author":"Campitelli","year":"2017","journal-title":"J. Clin. Med. Res."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Hou\u0161\u0165, J., Sp\u00ed\u017eek, J., and Havl\u00ed\u010dek, V. (2020). Antifungal Drugs. Metabolites, 10.","DOI":"10.3390\/metabo10030106"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Gintjee, T.J., Donnelley, M.A., and Thompson, G.R. (2020). Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. J. Fungi, 6.","DOI":"10.3390\/jof6010028"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1039\/C9CS00556K","article-title":"A comprehensive overview of the medicinal chemistry of antifungal drugs: Perspectives and promise","volume":"49","author":"Howard","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jiph.2022.08.004","article-title":"Development and research progress of anti-drug resistant fungal drugs","volume":"15","author":"Cui","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e00129-19","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of Olorofim (F901318) against Aspergillus Fumigatus, A. Nidulans, and A. Tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease","volume":"24","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_150","first-page":"2061","article-title":"FDA Public Workshop Summary\u2014Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs","volume":"74","author":"Yasinskaya","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e01735-19","DOI":"10.1128\/AAC.01735-19","article-title":"Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis","volume":"64","author":"Alkhazraji","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pharmthera.2018.10.008","article-title":"Antifungal drugs: New insights in research & development","volume":"195","author":"Nicola","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e00690","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_154","first-page":"EVIDoa2100055","article-title":"Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis","volume":"1","author":"Sobel","year":"2022","journal-title":"NEJM \u00c9vid."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Maione, A., Mileo, A., Pugliese, S., Siciliano, A., Cirillo, L., Carraturo, F., de Alteriis, E., De Falco, M., Guida, M., and Galdiero, E. (2023). VT-1161\u2014A Tetrazole for Management of Mono- and Dual-Species Biofilms. Microorganisms, 11.","DOI":"10.3390\/microorganisms11020237"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/AAC.02770-15","article-title":"The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii","volume":"60","author":"Lockhart","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e01071-18","DOI":"10.1128\/AAC.01071-18","article-title":"The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis","volume":"62","author":"Wiederhold","year":"2018","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/5\/884\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:30Z","timestamp":1760124750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/5\/884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":157,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["antibiotics12050884"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12050884","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}